Standout Papers

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer... 2004 2026 2011 2018 4.0k
  1. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer (2010)
    Philip W. Kantoff, Celestia S. Higano et al. New England Journal of Medicine
  2. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer (2004)
    Daniel P. Petrylak, Catherine M. Tangen et al. New England Journal of Medicine
  3. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (2008)
    Howard I. Scher, Susan Halabi et al. Journal of Clinical Oncology
  4. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer (2018)
    Matthew R. Smith, Fred Saad et al. New England Journal of Medicine
  5. Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer (2006)
    Eric J. Small, Paul F. Schellhammer et al. Journal of Clinical Oncology
  6. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 (2008)
    Brian I. Rini, Susan Halabi et al. Journal of Clinical Oncology
  7. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer (2009)
    Celestia S. Higano, Paul F. Schellhammer et al. Cancer
  8. Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer (2003)
    Susan Halabi, Eric J. Small et al. Journal of Clinical Oncology
  9. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (2017)
    Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology
  10. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer (2007)
    Eric J. Small, N. Simon Tchekmedyian et al. Clinical Cancer Research

Immediate Impact

20 by Nobel laureates 8 from Science/Nature 125 standout
Sub-graph 1 of 15

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023 Standout
14 intermediate papers

Works of Eric J. Small being referenced

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
2017 Standout
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
2008 Standout
and 7 more

Author Peers

Author Last Decade Papers Cites
Eric J. Small 23669 13948 6537 8706 603 34.8k
Celestia S. Higano 16423 10138 4819 6972 385 26.6k
Nicholas J. Vogelzang 22117 16878 5382 8203 693 40.8k
Neal D. Shore 16380 9214 5377 4687 752 24.3k
Johann S. de Bono 28295 21920 9653 18601 1.0k 51.9k
Stéphane Oudard 26909 13527 4752 16290 611 37.9k
Fred Saad 23140 14980 8399 7414 1.2k 35.4k
Martin Gleave 15695 8915 2415 15487 679 32.0k
W. Marston Linehan 21208 7535 2830 22532 581 44.8k
Cora N. Sternberg 20500 11771 4897 7408 578 33.5k
Mario A. Eisenberger 20808 8308 6040 5019 375 26.6k

All Works

Loading papers...

Rankless by CCL
2026